Search clinical trials for: Glecaprevir/pibrentasvir pediatric formulation

Total 75 results

AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Washington University School of Medicine

Recruiting

Feasibility and Acceptability of HCV Treatment in Pregnancy

Hepatitis C | Pregnancy Complications

United States
Tongji Hospital

Unknown

Glecaprevir/Pibrentasvir Real-world Study in China

Chronic Hepatitis c
Johns Hopkins University

Completed

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Hepatitis C | End Stage Renal Disease

United States
NYU Langone Health

Completed

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

Hepatitis C

United States
Massachusetts General Hospital

Withdrawn

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

End Stage Renal Disease | Chronic Hepatitis c

United States
Raymond Chung
Johns Hopkins University; University of Pennsylvania; Northwestern University; ... and other collaborators

Completed

Multi-center Study to Transplant Hepatitis-C Infected Kidneys (MYTHIC)

Hepatitis C | Renal Failure Chronic

United States
University of California, San Diego

Completed

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

Hepatitis C | Hepatitis C Virus Infection, Response to Therapy of

United States
Kirby Institute

Completed

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)

Hepatitis C, Chronic

United States, United Kingdom, Australia, France, New Zealand, Canada, Switzerland, Germany
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
AbbVie

Approved for marketing

Expanded Access to Glecaprevir/ Pibrentasvir

Hepatitis C Virus Infection

Slovenia
Johns Hopkins University

Completed

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

Hepatitis C | End Stage Renal Disease

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Hepatitis C Virus (HCV)

Brazil
University of Florida
AbbVie; University of North Carolina, Chapel Hill

Completed

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Hepatitis C | HCV

United States
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

United States, Australia, Austria, Canada, France, Germany, Italy, Spain
Sentara Norfolk General Hospital

Recruiting

Study of Hepatitis Eradication Receiving Protease Inhibitor Administration (SHERPA)

Coronary Artery Disease | Morality

United States
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; Maryland Department of Public Safety and Correctional...

Withdrawn

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) (ECLIPSE)

HCV Infection

United States
NYU Langone Health

Active, not recruiting

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

ESRD

United States
White River Junction Veterans Affairs Medical Center

Not yet recruiting

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

PTSD

United States
Id Care
AbbVie

Unknown

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study (ELIMINATEC)

Hepatitis C | Addict Heroin

United States
White River Junction Veterans Affairs Medical Center

Recruiting

Glecaprevir/Pibrentasvir for the Treatment of PTSD

PTSD

United States
Raymond T. Chung, MD

Withdrawn

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Kidney Diseases | Hepatitis C | Kidney Failure

United States
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
AbbVie

Completed

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Hepatitis C

United States, Australia, Belgium, Canada, Germany, New Zealand, Puerto Rico, United Kingdom
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie

Completed

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, France, Germany, Poland, Puerto Rico, Russian Federation, Spain, United Kingdom
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

Hepatitis C Virus (HCV)

United States, Canada, Germany, Greece, Italy, Korea, Republic of, Poland, Puerto Rico, Spain, Sweden
Weill Medical College of Cornell University
AbbVie

Recruiting

HCV Test and Treat Utilizing Simplified HCV Patient Education

Hepatitis C

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection (VOYAGE-1)

Hepatitis C Virus (HCV)

China, Korea, Republic of, Singapore
AbbVie

Completed

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection (VOYAGE-2)

Hepatitis C Virus (HCV)

China, Korea, Republic of
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
AbbVie

Completed

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) (ENDURANCE-4)

Hepatitis C Virus
Massachusetts General Hospital

Completed

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir (QUICK-CURE)

Hepatitis C | Kidney Disease, Chronic | Kidney Failure

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Chronic Hepatitis C | Hepatitis C Virus
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Kirby Institute
Flinders University; South Australian Health and Medical Research Institute

Recruiting

Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (SCALE-C)

Liver Diseases | Digestive System Diseases | RNA Virus Infections | Hepatitis | Hepatitis, Viral, Human | Hepatitis C

Australia
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); AbbVie

Completed

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

HIV Infection | Hepatitis C Infection

United States, Brazil
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
Actelion

Completed

Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Healthy Subjects

Germany
Bayer

Completed

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Pharmacokinetics

Germany
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Influenza

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)

Hepatitis C Virus | Chronic Hepatitis C Virus

3

Subscribe